

## *Onxeo Announces its Financial Agenda for 2021*

Paris (France), January 7, 2021 – 6 pm CET – **Onxeo S.A.** (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“**Onxeo**” or “the **Company**”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) in oncology, in particular against rare or resistant cancers, today announced its financial agenda for 2021.

Event	Date*
Full-year 2020 results	Tuesday, March 30, 2021
Shareholders’ general meeting	Wednesday, May 12, 2021
Half-year 2021 results	Wednesday, July 28, 2021

\* This preliminary agenda may be modified. Press releases are published after financial markets close.

### About Onxeo

**Onxeo** (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

**platON™** is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline.

**AsiDNA™**, the first compound from platON™, is a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a decoy and agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the distinctive properties of AsiDNA™, notably its ability to abrogate tumor resistance to PARP inhibitors regardless of the genetic mutation status. AsiDNA™ has also shown a strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors. The DRIIV-1 (DNA Repair Inhibitor-administered IntraVenously) phase I study has evaluated AsiDNA™ by systemic administration (IV) in advanced solid tumors and confirmed the active doses as well as a favorable human safety profile. The ongoing DRIIV-1b extension study is assessing the safety and efficacy of a 600 mg dose of AsiDNA™ in combination with carboplatin and then with carboplatin and paclitaxel, in patients with solid tumors who are eligible for such treatments.

**OX401** is a new drug candidate from platON™, optimized to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. OX401 is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.

For further information, please visit [www.onxeo.com](http://www.onxeo.com).

### Forward looking statements

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to chapter 3 “Risk



Factors" ("*Facteurs de Risque*") of the Company's universal registration document filed with the *Autorité des marchés financiers* on April 27, 2020 under number D.20-0362, which is available on the websites of the *Autorité des marchés financiers* ([www.amf-france.org](http://www.amf-france.org)) and the Company ([www.onxeo.com](http://www.onxeo.com)).

## Contacts

### Onxeo

Valerie Leroy,  
Investor Relations

[investors@onxeo.com](mailto:investors@onxeo.com)

+33 1 45 58 76 00

### Media Relations

Nicolas Merigeau  
NewCap

[onxeo@newcap.eu](mailto:onxeo@newcap.eu)

+33 1 44 71 94 98

### Investor Relations / Strategic Communication

Dušan Orešanský / Emmanuel Huynh  
NewCap

[onxeo@newcap.eu](mailto:onxeo@newcap.eu)

+33 1 44 71 94 92

### Investor Relations US

Brian Ritchie

LifeSci Advisors

[britchie@lifesciadvisors.com](mailto:britchie@lifesciadvisors.com)

+1 212 915 2578